Craif Raises $33M Series D for U.S. Cancer Test Push

Craif has closed an approximately $33M Series D to finance the next stage of its urine-based cancer-testing platform, moving from commercial scale in Japan toward a clinical and reimbursement buildout in the United States. Granite-Integral and TAUNS Laboratories co-led the round, with new and returning investors across Singapore, the United States, and Japan.

The headline number needs a footnote. Craif's English announcement says the $33M package includes equity, debt, and a secondary transaction, while the Japanese disclosure reports approximately ¥5.3B across those components. That means the total should not be read as $33M of entirely new cash entering the company.

What happened in Craif's Series D

Craif announced the round on August 18, 2026, one day after publishing the original Japanese release. The company said Granite-Integral and diagnostic-test manufacturer TAUNS Laboratories served as co-leads. Unreasonable Group, X&KSK, Nagase Future Fund No. 1, Kodomo no Mori, Hokuyo Startup Fund No. 1, other institutions, individuals, and several Japanese banks also participated.

The transaction combines growth financing with a measure of shareholder liquidity. Craif's Japanese release breaks out roughly ¥4.8B across a third-party allotment and secondary sales, including about ¥900M of secondary transactions, plus ¥500M in debt. Craif also reports approximately ¥14.2B, or $88M, in cumulative funding since its 2018 founding, but that lifetime total includes equity, financing, and grants rather than venture equity alone.

No valuation was disclosed. The company said proceeds will support U.S. research and development, a prospective pancreatic-cancer study, expansion of its clinical team, preparation for a reimbursement-oriented U.S. launch, and continued regulatory work on a pancreatic-cancer software medical device program in Japan.

What Craif has built in Japan

Craif's platform analyzes microRNA found in urine and uses AI to assess signals associated with disease risk. The company positions urine as a non-invasive sample that can be collected more easily than blood, then applies its biomarker-analysis platform to identify patterns that may warrant further clinical attention. Its miSignal service is currently offered in Japan as a cancer-risk test, not as a substitute for a medical diagnosis.

The operating base is meaningful for a diagnostics startup. Craif says miSignal is available through more than 2,500 medical institutions and 4,700 pharmacies and drugstores, with more than 110,000 tests performed. The company also reports more than 85 peer-reviewed papers and conference presentations, although those publication and deployment counts remain company-reported metrics.

The scientific record gives the U.S. expansion substance without removing the need for more evidence. A peer-reviewed pancreatic-cancer study indexed by PubMed evaluated a urinary extracellular-vesicle microRNA assay across 153 pancreatic-cancer cases and 309 non-cancer participants. The results showed strong discrimination in the study population, but the authors noted sample-size limitations, and the paper disclosed Craif funding and author conflicts.

Why the U.S. buildout is the real test

Craif opened a company-operated bio-AI laboratory in San Diego in April 2026 after establishing a U.S. subsidiary and joining JLABS San Diego. The company says it is working with 30 medical institutions across 15 states and plans a prospective study focused on pancreatic cancer. Those relationships and the new laboratory provide a base for evidence generation, but they do not amount to U.S. regulatory clearance or reimbursement.

CEO and co-founder Ryuichi Onose relocated to San Diego to lead the U.S. business. Craif has also appointed Nicholas "Nick" Bevins, MD, PhD, as chief medical officer to direct clinical development, while CTO Yuki Ichikawa remains a central technical leader and Takeo Mukai joined as CFO in April. The hiring pattern shows that Craif is assembling the clinical, financial, and operating functions needed to move beyond a research beachhead.

That distinction matters in diagnostics. A promising biomarker, a strong retrospective study, a functioning laboratory, and a commercial product in another country are important inputs, but U.S. adoption depends on prospective evidence, a compliant testing operation, clinical utility, and an economic case that payers can evaluate. The Series D is designed to finance that evidence chain rather than pretend it has already been completed.

What the investor group is underwriting

The co-leads bring different forms of credibility. Granite-Integral connects an Asia-focused investment platform with Japanese private-equity experience, while TAUNS combines capital with operating knowledge in rapid diagnostics and an existing commercial relationship with Craif. Returning investors Unreasonable Group and X&KSK add continuity as the company shifts from domestic scale toward a global clinical strategy.

The secondary component is also notable. It provides liquidity to some existing corporate holders while new equity and debt fund expansion, allowing Craif to adjust its ownership structure without waiting for an acquisition or public listing. That structure is not inherently good or bad, but it makes the $33M headline more informative when the components are visible.

For investors, the bet rests on whether Craif can turn its Japan-derived data, distribution footprint, and scientific work into a product that fits U.S. clinical workflows. The capital is funding translation across markets, not merely another laboratory experiment. That is a more difficult assignment, and it is also where a diagnostics platform can create durable value if the evidence holds.

What this round signals for bio-AI diagnostics

Craif's financing reflects a broader shift in healthcare AI from software-only claims toward systems that combine biological data, wet-lab operations, clinical studies, and machine learning. The model can produce defensible datasets and repeatable testing infrastructure, but it also requires more capital and patience than a conventional enterprise-software launch.

The company now has a clear sequence of proof points. It needs to execute the prospective pancreatic-cancer study, build its U.S. clinical operation, clarify the launch and reimbursement pathway, and advance the Japanese regulatory program without overstating what current evidence can support. Success will be measured less by the size of this round than by whether Craif can reproduce clinical usefulness across a new healthcare system.

The Series D gives Craif room to attempt that translation. It also places the company in a more demanding phase, where adoption metrics from Japan, peer-reviewed studies, and investor confidence must become prospective evidence, regulatory progress, and payer relevance in the United States. That is the difference between exporting a test and building a diagnostics company across borders.